← Markets

Tempus AI, Inc.

TEM · NASDAQ

Market closed$52.47$-1.12 (-2.09%)After hours $52.43 · -0.08%

Key statistics

Previous close$53.59
Open$51.80
Day high$53.50
Day low$51.23
52-week high$104.32
52-week low$41.73
Market cap9.16B
Volume3.70M
Average volume6.27M
P/E ratio-104.94
Forward P/E—
EPS-0.50
Dividend yield0.00%

Market context

Why it moved

TEM shares declined amid a broader momentum meltdown affecting AI-related stocks, with lingering concerns about the AI sector weighing on sentiment across momentum-driven names.

ToptradersunpluggedStockinvestNtxe NewsYahooRealinvestmentadvice

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Tempus AI declined amid a broad healthcare sector pullback and risk-off sentiment driven by escalating U.S.-Iran tensions and a tech/AI selloff that dragged the Nasdaq lower. A key company catalyst was the July 16 publication of landmark NHS study results in Nature Digital Medicine, validating the Paige Prostate AI Suite's real-world ability to accelerate diagnostic turnaround times and reduce lab workloads. Despite this positive clinical data, the stock faces ongoing investor skepticism around monetization timelines, with the average analyst price target around $68.54, heavy insider selling over the past 90 days, and a 52-week range of $41.73–$104.32 reflecting significant volatility.

-2.0899

July 17, 2026Tempus AI tumbled sharply as tech and growth stocks broadly sold off amid a rotation out of richly valued AI names, with the Nasdaq declining while the healthcare sector saw mixed signals. Despite positive news — including a landmark Nature Digital Medicine publication highlighting Tempus's Paige Prostate AI Suite improving diagnostic consistency and turnaround times across UK NHS hospitals — shares fell notably, underperforming the broader healthcare sector (XLV). The stock continues to trade well below its 52-week high of $104.32, and a recent Seeking Alpha analysis pegged fair value near $62.55, citing slowing growth and cash burn concerns even as analysts maintain a consensus Hold with a $68.54 average price target.

-6.393

July 16, 2026Tempus AI fell over 2% as insider selling activity and mixed analyst sentiment weighed on shares, even as institutional investors continued building positions. Notable insider sales by CEO Eric Lefkofsky and other executives totaling 616,043 shares over the past 90 days have tempered enthusiasm, while analysts maintain a Hold consensus with a $68.54 average price target—well above current levels. The broader healthcare sector provided limited support, with XLV holding near flat amid sector-wide headwinds including HCA Healthcare cutting its profit forecast and hospital stocks under pressure from rising nursing costs.

-2.4203

July 15, 2026Tempus AI shares rallied nearly 5%, outperforming a modestly higher broader market, as investor sentiment improved amid a cooler-than-expected June CPI report that lifted growth and AI-linked names. Analysts maintain a consensus price target of $68.54 with a majority Buy/Hold split, while the company's Q1 beat—36.1% revenue growth and an EPS outperformance of $0.08—continues to underpin a rebound narrative, even as notable insider selling and a still-negative net margin keep some investors cautious.

4.899

July 14, 2026Tempus AI shares fell nearly 4% as a broad risk-off sell-off — triggered by renewed U.S.-Iran military exchanges and a sharp spike in oil prices — weighed on growth and AI-linked equities. The decline came despite a Seeking Alpha piece highlighting the company's 'healthcare data dominance' thesis and continued institutional accumulation, including Diversify Wealth Management raising its stake by 86% in Q1. Analyst consensus remains Hold with a $68.54 price target, well above current levels, while the stock's high beta (3.46) amplified the macro-driven pullback against a backdrop of healthcare sector underperformance heading into Q2 earnings season.

-3.9499

July 11, 2026Tempus AI tumbled roughly 5% as a confluence of headwinds weighed on investor sentiment: CEO Eric Lefkofsky's affiliated entities recently sold $9.6 million in shares, and Freedom Capital initiated coverage with only a Hold rating and a $59 price target, citing valuation as 'about right.' Compounding the pressure, insider selling has been broad—executives including the CFO and CAO have also sold shares recently, with insiders offloading nearly 583,000 shares over the past 90 days. The broader healthcare sector (XLV) also dipped modestly, while geopolitical tensions in the Middle East added to overall market caution, though the S&P 500 closed near 52-week highs.

-5.3171

July 10, 2026Tempus AI surged nearly 7.4%, outperforming the broader healthcare sector (XLV essentially flat) and S&P 500, as investors rallied around the company's 'AI as physician' narrative and strong fundamental momentum. The move comes amid healthcare's continued sector leadership — up 6.6% in June alone — and renewed enthusiasm for Tempus AI's differentiated data platform, which boasts 45M+ de-identified records and expanding pharma partnerships. Despite recent CEO-linked insider selling (~$9.6M in late June) and a mixed analyst consensus (Hold, $68.54 avg. target), bullish sentiment has surged on Tempus AI's 36% YoY revenue growth and a better-than-expected Q1 loss of $0.13/share vs. the $0.21 consensus.

7.3861

July 9, 2026Tempus AI shares tumbled nearly 5% on Wednesday, underperforming the broader healthcare sector as a global risk-off selloff — triggered by President Trump declaring the U.S.-Iran ceasefire 'over' and sending oil prices surging over 5% — hit growth and high-beta names hardest. With a beta of 3.62, TEM is particularly sensitive to macro shocks, and the stock sits well below its 52-week high of $104.32 despite recent positive catalysts including a Q1 earnings beat ($0.13 loss vs. $0.21 expected) and 36.1% YoY revenue growth; a CEO-linked $9.6M share sale has also clouded near-term sentiment.

-4.693

Simply Wall Street · July 17, 2026How Do Tempus AI’s (TEM) NHS Prostate Results Shape Its Clinical Credibility Narrative?Investing.com · July 16, 2026Guggenheim raises Tempus AI stock price target to $65 on estimatesBusiness Wire · July 16, 2026Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health ServiceBusiness Wire · July 9, 2026Tempus to Report Second Quarter 2026 Financial Results on July 30Seeking Alpha · May 22, 2026Tempus AI: Taking Advantage Of Investor Myopia (NASDAQ:TEM)Stocktwits · May 21, 2026Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic PatientsStock Titan · May 6, 2026Tempus tool will identify patients for Alzheimer’s blood testingStock Titan · May 5, 2026Why Tempus raised its 2026 forecast after 36% revenue growth
Benzinga · July 16, 2026Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $65
Benzinga · July 1, 2026Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI
Benzinga · July 1, 2026Freedom Capital Markets Initiates Coverage On Tempus AI with Hold Rating, Announces Price Target of $59
Benzinga · June 25, 2026Tempus AI Enters Research Collaboration With Angiosarcoma Awareness To Accelerate Data-Driven Research In Angiosarcoma
Benzinga · June 11, 2026Tempus AI Announces Publication Of A Successful Multi-Site Software Validation
Benzinga · June 9, 2026Ambry Study Shows RNA Testing May Clarify Uncertain Genetic Results
Benzinga · June 4, 2026Why Tempus AI Stock Is Surging On Thursday?
Benzinga · June 1, 2026Tempus AI Announces Upcoming Clinical Availability Of xH, Next-Gen Whole-Genome Sequencing Test

Peers

S&P 500SPX · $7,457.69-1.01%Guardant Health, Inc.GH · $155.87+0.56%Natera, Inc.NTRA · $271.39+0.58%NeoGenomics, Inc.NEO · $14.61-1.55%Veeva Systems Inc.VEEV · $195.38-1.01%IQVIA Holdings Inc.IQV · $206.26-2.01%Revvity, Inc.RVTY · $110.15-1.39%Bio-Techne CorporationTECH · $72.12+0.49%Charles River Laboratories International, Inc.CRL · $224.35-2.10%Qiagen N.V.QGEN · $41.15-0.87%Avantor, Inc.AVTR · $11.07-1.69%Health Catalyst, Inc.HCAT · $2.25-1.32%